Iyo Bank Ltd. Grows Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Key Points

• Iyo Bank Ltd. increased its ownership in Thermo Fisher Scientific by 38%, acquiring an additional 4,140 shares, bringing its total to 15,049 shares valued at approximately $7.49 million.
• CEO Marc N. Casper sold 8,000 shares of the stock, resulting in a 6.49% decrease in his ownership, while insiders have collectively sold 18,400 shares recently.
• Thermo Fisher Scientific has a current market capitalization of $174.68 billion, with a PE ratio of 26.75 and a forecasted earnings per share of 23.28 for the fiscal year.

Iyo Bank Ltd. boosted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 38.0% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,049 shares of the medical research company's stock after buying an additional 4,140 shares during the quarter. Thermo Fisher Scientific makes up approximately 2.4% of Iyo Bank Ltd.'s portfolio, making the stock its 16th biggest position. Iyo Bank Ltd.'s holdings in Thermo Fisher Scientific were worth $7,488,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. GAMMA Investing LLC grew its holdings in shares of Thermo Fisher Scientific by 60,610.9% in the first quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company's stock valued at $1,203,859,000 after acquiring an additional 2,415,346 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its stake in Thermo Fisher Scientific by 86.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,083,900 shares of the medical research company's stock valued at $1,604,338,000 after purchasing an additional 1,433,444 shares during the last quarter. Nuveen LLC purchased a new stake in shares of Thermo Fisher Scientific during the first quarter worth $532,360,000. Kovitz Investment Group Partners LLC lifted its position in shares of Thermo Fisher Scientific by 1,905.4% during the fourth quarter. Kovitz Investment Group Partners LLC now owns 903,232 shares of the medical research company's stock worth $469,889,000 after acquiring an additional 858,193 shares in the last quarter. Finally, Farallon Capital Management LLC raised its position in shares of Thermo Fisher Scientific by 73.8% in the fourth quarter. Farallon Capital Management LLC now owns 1,233,256 shares of the medical research company's stock worth $641,577,000 after buying an additional 523,800 shares in the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Trading Up 0.2%

NYSE:TMO traded up $0.83 on Thursday, hitting $485.62. The stock had a trading volume of 1,955,228 shares, compared to its average volume of 2,498,410. The company has a fifty day moving average price of $431.32 and a two-hundred day moving average price of $462.11. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $627.88. The stock has a market cap of $183.38 billion, a price-to-earnings ratio of 28.09, a PEG ratio of 2.55 and a beta of 0.74.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same period in the prior year, the business earned $5.37 EPS. The firm's quarterly revenue was up 2.9% on a year-over-year basis. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 9.95%.

Analyst Ratings Changes

TMO has been the topic of a number of research analyst reports. Barclays increased their target price on Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an "equal weight" rating in a research note on Thursday, July 24th. Hsbc Global Res cut Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 24th. Argus dropped their target price on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a report on Tuesday, April 29th. Royal Bank Of Canada lowered their price objective on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Finally, Scotiabank upgraded shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective for the company in a report on Friday, July 11th. Seven investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and a consensus price target of $593.00.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $451.82, for a total value of $4,518,200.00. Following the sale, the chief executive officer owned 115,174 shares of the company's stock, valued at $52,037,916.68. The trade was a 7.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares in the company, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 18,400 shares of company stock worth $8,345,792 over the last three months. 0.33% of the stock is currently owned by insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.